18143-Endometrial Cancer-NA-580

Endometrial Cancer

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)(MK-7902-001-00)

  • Details

ClinicalTrials.gov ID: NCT03884101
Diagnosis Type: NA
USOR Number:

  • Address

2070 W. Rudasill Rd., #130
Tucson, AZ 85704
P: (520) 797-4468

Search by practice name, trial titles, indicators and specific disease types.